Free equity investment tool of Japanese companies

Credit Rating Analysis

Annual

First quarter

Second quarter

Third quarter

Sponsored Link

Related Company

Nichi-Iko Pharmaceutical

Kuraray

ダイセル

エスケー化研

Nissan Chemical Industries

Aica Kogyo

アステラス製薬

Hitachi Chemical

富士製薬工業

ROHTO PHARMACEUTICAL

Takeda Pharmaceutical

Fuso Pharmaceutical Industries

Mitsubishi Tanabe Pharma

長谷川香料

Toray Industries

EDIUNET Related Ranking

EDIUNET

EDIUNET Credit Rating

EDIUNET Industry Avg

EDIUNET Prefectures

Yuho! Industry

EDIUNET Rating News

Prev « 2024-04 » Next

Mon	Tue	Wed	Thu	Fri	Sat	Sun
1 -	2 -	3 -	4 -	5 -	6 -	7 -
8 -	9 -	10 -	11 -	12 -	13 -	14 -
15 -	16 -	17 -	18 -	19 -	20 -	21 -
22 -	23 -	24 -	25 -	26 -	27 -	28 -
29 -	30 -

[Update list]

1/28 Retail Trade (CAWACHI:A etc...

1/27 Banks (The Awa Bank:BBB→A)

1/23 Chemicals (Milbon:AA→AAA)

1/21 Glass & Ceramics Products (..

1/21 Machinery (TSUDAKOMA:C)

1/21 Other Services (Netindex.:CC)

1/20 Other Products (Kurogane Kos..

1/20 Wholesale Trade (リーバイ・..

1/20 Other Services (川崎地質:BB→..

1/17 Chemicals (Kawaguchi Chemica..

 RSS

 Company RSS

 Daily RSS

Sponsored Link

Recently Download Chart

SANKEI CHEMICAL

ROHM

Yushiro Chemical Indutry

メルコホールディングス

Hitachi Zosen etc.

Credit Rating Analysis: Fuso Pharmaceutical Industries (Annual )

The details of credit rating (bankruptcy risk) can be checked. A credit rating in nine stages (AAA-C).

【Analysis Menu】 Outline Statement Rating Indicator Download

Sponsored Link

Credit Rating (Bankruptcy Risk): Fuso Pharmaceutical Industries (Annual ) Consolidated | Non-Consolidated

Date	Credit Rating	Comment	Sales	Current Profit	Net Income
2013-03-31	BBB	Credit is enough, but be decreased potential by biz environs.	¥ 48 B 9.59%	¥ 3 B 4,986.48%	¥ 4 B 1,209.40%

Financial Timeline

Date	2012-06-30  (First quarter )	2012-09-30  (Second quarter )	2012-12-31  (Third quarter )	2013-03-31  (Annual )
Credit Rating	BB	BBB	BBB	BBB
Total Assets	¥ 69 B	¥ 70 B	¥ 71 B	¥ 71 B
Net Assets	¥ 33 B	¥ 34 B	¥ 31 B	¥ 33 B

Financial Statement Risk Analysis: Fuso Pharmaceutical Industries (Annual ) (Consolidated )

Special note

Net Assets have increased 5consecutive terms. The fiscal base is getting better.

[Date: 2013-03-31]  Danger : Warning : Caution : Good

Dividend
Under the situation of Net Income (¥ 4 B) & Operating Cash Flow (¥ 3 B) , Dividend (¥ -543 M) is paid.

[Date: 2012-03-31]  Danger : Warning : Caution : Good

Management Risk (*Sales is decrease )
Sales (¥ 44 B) is first term Sales (¥ 47 B) less , there is a possibility that the management situation has stagnated and deteriorated

Management Risk (*Net Income is decrease )
Net Income (¥ 372 M) is first term Net Income (¥ 1 B) less , there is a possibility that the management situation has stagnated and deteriorated

Management Risk (*Net Profit Margin is decrease )
Net Profit Margin (0.84％) is first term Net Profit Margin (2.41％) less , there is a possibility that the profitability has deteriorated.

Dividend
Under the situation of Net Income (¥ 372 M) & Operating Cash Flow (¥ 884 M) , Dividend (¥ -543 M) is paid.

Financing Risk (*Interest-bearing Debt more)
Sales first term ratio (¥ -3 B) & Operating Cash Flow first term ratio (¥ -6 B) is a minus, Interest-bearing Debt (¥ 13 B) is first term Interest-bearing Debt (¥ 12 B) more , there is a possibility that the financing has deteriorated very much.

Non-performing asset Risk (*Accounts Receivable and Inventory, etc. confirmed content)
Other Current Assets first term ratio (¥ 1 B) is Sales first term ratio (¥ -3 B) more , there is a possibility that the non-performing asset was increased.

[Date: 2011-03-31]  Danger : Warning : Caution : Good

Financing Good (*Operating Cash Flow is plus )
Investment Cash Flow (¥ -1 B) & Financial Cash Flow (¥ -4 B) is a minus, Operating Cash Flow (¥ 6 B) is a plus,

Dividend
Under the situation of Net Income (¥ 1 B) & Operating Cash Flow (¥ 6 B) , Dividend (¥ -543 M) is paid.

[Date: 2010-03-31]  Danger : Warning : Caution : Good

Financing Good (*Operating Cash Flow is plus )
Investment Cash Flow (¥ -1 B) & Financial Cash Flow (¥ -878 M) is a minus, Operating Cash Flow (¥ 2 B) is a plus,

Dividend
Under the situation of Net Income (¥ 518 M) & Operating Cash Flow (¥ 2 B) , Dividend (¥ -543 M) is paid.

Non-performing asset Risk (*Accounts Receivable and Inventory, etc. confirmed content)
Other Current Assets first term ratio (¥ 1 B) is Sales first term ratio (¥ 659 M) more , there is a possibility that the non-performing asset was increased.

[Date: 2009-03-31]  Danger : Warning : Caution : Good

Management Risk (*Net Income is minus or 0 )
Net Income (¥ -931 M) is minus or 0, so , there is a possibility that the management situation is severe.

Dividend Risk
Under the situation of Net Income (¥ -931 M) & Operating Cash Flow (¥ 1 B), Dividend (¥ -543 M) is paid.

Overinvestment Risk (*Investment Cash Flow confirmed content)
Net Income (¥ -931 M) is a minus, the cashflow of Operating Cash Flow (¥ 1 B) is smaller than Investment Cash Flow (¥ -2 B) , there is a possibility of the overinvestment.

Credit Rating (Bankruptcy Risk): Fuso Pharmaceutical Industries (Annual ) Consolidated | Non-Consolidated

Date	Credit Rating	Comment	Sales	Current Profit	Net Income
2013-03-31	CCC	Credit is fragile, and depended on biz environs.	¥ 48 B 9.61%	¥ 3 B 4,963.51%	¥ 4 B 1,731.20%

Financial Timeline

Date	-  (Third quarter )	2013-03-31  (Annual )	2013-06-30  (First quarter )	2013-09-30  (Second quarter )
Credit Rating	-	CCC	-	-
Total Assets	-	¥ 52 B	¥ 69 B	¥ 70 B
Net Assets	-	¥ 33 B	¥ 33 B	¥ 34 B

Financial Statement Risk Analysis: Fuso Pharmaceutical Industries (Annual ) (Non-Consolidated )

Special note

Net Assets have increased 5consecutive terms. The fiscal base is getting better.

[Date: 2013-03-31]  Danger : Warning : Caution : Good

Stated Capital less
As compared with the first term of Stated Capital (¥ 10 B), Stated Capital (-) is less than 10%, , there is a possibility that the management situation is extremely severe.

[Date: 2012-03-31]  Danger : Warning : Caution : Good

Management Risk (*Sales is decrease )
Sales (¥ 44 B) is first term Sales (¥ 47 B) less , there is a possibility that the management situation has stagnated and deteriorated

Management Risk (*Net Income is decrease )
Net Income (¥ 266 M) is first term Net Income (¥ 1 B) less , there is a possibility that the management situation has stagnated and deteriorated

Management Risk (*Net Profit Margin is decrease )
Net Profit Margin (0.60％) is first term Net Profit Margin (2.35％) less , there is a possibility that the profitability has deteriorated.

Dividend
Under the situation of Net Income (¥ 266 M) & Operating Cash Flow (-) , Dividend (¥ -543 M) is paid.

Non-performing asset Risk (*Accounts Receivable and Inventory, etc. confirmed content)
Other Current Assets first term ratio (¥ 1 B) is Sales first term ratio (¥ -3 B) more , there is a possibility that the non-performing asset was increased.

[Date: 2011-03-31]  Danger : Warning : Caution : Good

Dividend
Under the situation of Net Income (¥ 1 B) & Operating Cash Flow (-) , Dividend (¥ -543 M) is paid.

[Date: 2010-03-31]  Danger : Warning : Caution : Good

Dividend
Under the situation of Net Income (¥ 511 M) & Operating Cash Flow (-) , Dividend (¥ -543 M) is paid.

Non-performing asset Risk (*Accounts Receivable and Inventory, etc. confirmed content)
Other Current Assets first term ratio (¥ 1 B) is Sales first term ratio (¥ 657 M) more , there is a possibility that the non-performing asset was increased.

[Date: 2009-03-31]  Danger : Warning : Caution : Good

Management Risk (*Net Income is minus or 0 )
Net Income (¥ -939 M) is minus or 0, so , there is a possibility that the management situation is severe.

Dividend
Under the situation of Net Income (¥ -939 M) & Operating Cash Flow (-) , Dividend (¥ -543 M) is paid.

Related Information: Fuso Pharmaceutical Industries (Annual )

Statement Type

Annual : Fuso Pharmaceutical Industries

First quarter : Fuso Pharmaceutical Industries

Second quarter : Fuso Pharmaceutical Industries

Third quarter : Fuso Pharmaceutical Industries

Analysis Menu

Outline : Fuso Pharmaceutical Industries

Statement : Fuso Pharmaceutical Industries

Rating : Fuso Pharmaceutical Industries

Indicator : Fuso Pharmaceutical Industries

Download : Fuso Pharmaceutical Industries

Industry Comparison Ranking

Chemicals - EDIUNET Industry Rankings

Chemicals - EDIUNET Credit Rating

Chemicals - EDIUNET Industry Avg

Comparison with a neighboring company

Osaka - EDIUNET Prefectures

Osaka大阪市 - EDIUNET Prefectures

Related company's newest statement

Date	Company	Credit Rating	Date
1/23	Milbon	AA→AAA	2013-12-20
1/17	Kawaguchi Chemical Indu..	BBB→BB	2013-11-30
1/17	SANKEI CHEMICAL	A	2013-11-30
1/15	HOKKO CHEMICAL INDUSTRY	BB→B	2013-11-30
1/15	Daito Pharmaceutical Co .	AA	2013-11-30 (Q2)
1/15	KAWAKAMI PAINT MFG.	B→BB	2013-11-30
1/15	旭化学工業	AA	2013-11-30 (Q1)
1/10	OSAKA ORGANIC CHEMICAL ..	BB→BBB	2013-11-30
1/10	HISAMITSU PHARMACEUTICAL	A	2013-11-30 (Q3)
1/10	AMS Life Science	BBB→BB	2013-11-30 (Q1)

EDIUNET Investment News (Chemicals)

1/23 Chemicals (Milbon:AA→AAA)

1/17 Chemicals (Kawaguchi Chemica..

1/15 Chemicals (HOKKO CHEMICAL IN..

1/10 Chemicals (OSAKA ORGANIC CHE..

1/9 Chemicals (SANKO GOSEI:A)

12/27 Chemicals (Niitaka:A)

12/18 Chemicals (KUMIAI CHEMICAL I..

12/12 Chemicals (IHARA CHEMICAL IN..

12/11 Chemicals (Konoshima Chemica..

12/10 Chemicals (NATOCO:AA)

Company Information

Ticker	Market	Industry	Month	report	Rating
Fuso Pharmaceutical Industries	4538	TSE 1st	Chemicals	3	Annual	BBB

Related Company

キョーリン製薬ホールディングス (Sales ¥ 107 B)

ONO PHARMACEUTICAL (Sales ¥ 145 B)

MANDOM (Sales ¥ 60 B)

Otsuka Holdings (Sales ¥ 1.2 T)

ROHTO PHARMACEUTICAL (Sales ¥ 129 B)

Takeda Pharmaceutical (Sales ¥ 1.5 T)

Hitachi Chemical (Sales ¥ 464 B)

Nichi-Iko Pharmaceutical (Sales ¥ 93 B)

Nissan Chemical Industries (Sales ¥ 153 B)

キッセイ薬品工業 (Sales ¥ 62 B)

千寿製薬 (Sales ¥ 28 B)

Aica Kogyo (Sales ¥ 101 B)

エスケー化研 (Sales ¥ 82 B)

関連する株式投資情報

EDIUNET Caution

*Financial data might be different from the actual one. Please confirm the original, and read Caution.

*This site has obtained the information from the FSA's EDINET, Tokyo Stock Exchange's TDnet and Pay statistical data services, Fukuoka stock Exchange's Stock market capitalization, Center for Spatial Information Science's CSV Geocoding Service. The copyright of the information belongs to each corporation etc. .